GLP-1 receptor agonists explained for researchers

A GLP-1 receptor agonist is a molecule that binds to and activates the glucagon-like peptide-1 receptor, a class B G protein-coupled receptor that native GLP-1 uses to signal. The receptor's mechanism links to glucose-dependent insulin secretion, lower glucagon secretion when glucose is high, slower gastric emptying, and satiety signals in the brain. Native GLP-1 lasts only minutes before the enzyme DPP-4 breaks it down, so drug molecules such as semaglutide are engineered to resist that enzyme and stay in circulation for days. This guide explains the incretin system, how GLP-1 compares with its partner hormone GIP, and how the licensed medicines differ from research-grade powders.

The incretin system in brief

The incretin concept dates to Creutzfeldt in the 1970s, who noted that glucose taken by mouth triggers a much larger insulin response than the same glucose given intravenously. The difference comes from hormones released by the gut in response to nutrients. Two hormones carry most of this effect:

• GIP (glucose-dependent insulinotropic polypeptide), made by enteroendocrine K cells in the upper small intestine, the duodenum and jejunum.
• GLP-1 (glucagon-like peptide-1), made by L cells spread through the lining of the distal gut, the ileum and colon.

A 2024 review in Frontiers in Endocrinology notes that both hormones are broken down by dipeptidyl peptidase 4 (DPP-4), that their half-lives are measured in minutes, and that only a small fraction of the active hormone reaches the general circulation. That short life is the central design problem for anyone trying to use the pathway pharmacologically.

How the GLP-1 receptor mechanism works

GLP-1R is a class B, seven-transmembrane G protein-coupled receptor. When an agonist binds, the receptor activates adenylate cyclase and raises intracellular cAMP, a pathway shared with the GIP receptor. The downstream effects described in the review literature and in regulator product information include:

The glucose dependence is an important point for experimental design. Because insulin release is stimulated mainly when glucose is raised, results in cell or islet models depend heavily on the glucose concentration used in the assay medium.

GLP-1 vs GIP: how the two incretin peptides compare

The blunted response to GIP in type 2 diabetes long made it the less obvious drug target. The development of dual agonists changed that picture. The same review describes tirzepatide as the only FDA-approved dual GIP/GLP-1 receptor agonist and notes it is designed to act more strongly at the GIP receptor than at the GLP-1 receptor.

How drug molecules outlast native GLP-1

Semaglutide is the clearest worked example of the engineering. The EU product information describes it as a GLP-1 analogue with 94% sequence homology to human GLP-1. RCSB PDB-101 lists three changes:

• Alanine to Aib at position 8. Aib (α-aminoisobutyric acid) makes the peptide a much poorer DPP-4 substrate without significantly changing receptor binding.
• Lysine to arginine at position 34.
• Acylation of the lysine at position 26 with a spacer and a C-18 fatty diacid, which increases binding to albumin.

The EU product information gives a half-life of around one week and names albumin binding as the main mechanism of protraction. PDB-101 cites about 165 hours from the original discovery paper and roughly 13 hours for the earlier analog liraglutide. Our semaglutide vs tirzepatide vs retatrutide comparison sets the three molecules side by side.

Beyond GLP-1: dual and triple agonists

Retatrutide adds the glucagon receptor as a third target. Its Phase 2 obesity trial was published in the New England Journal of Medicine in June 2023, and Phase 3 trials are covered in our TRIUMPH-4 explainer. The evidence for all three molecules comes from controlled clinical trials of the licensed or investigational products. That evidence does not transfer to unregulated powders of uncertain identity and purity.

Licensed medicines vs research-grade powder

The approved medicines are specific products: Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide). Their manufacture, formulation and quality are reviewed by regulators. In the EU, for example, Ozempic's semaglutide is made in Saccharomyces cerevisiae cells by recombinant DNA technology.

Research-grade semaglutide, tirzepatide or retatrutide sold online is not the approved product. The FDA's page on unapproved GLP-1 drugs, updated 1 October 2026, says unapproved versions do not undergo FDA review for safety, effectiveness and quality. It names semaglutide, tirzepatide, retatrutide, survodutide and mazdutide sold "for research purposes" but marketed to consumers, and urges consumers not to buy them. It also states that retatrutide and cagrilintide cannot be used in compounding under federal law, and that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from those in approved drugs. For enforcement history see our FDA warning letters tracker, and for the legal background see are peptides legal?

Frequently asked questions

Sources

1. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (2024)
2. European Medicines Agency: Ozempic EPAR product information
3. RCSB PDB-101: Semaglutide
4. FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated 1 October 2026)
5. FDA news release: FDA approves new drug treatment for chronic weight management, first since 2014 (4 June 2021)
6. FDA news release: FDA approves new medication for chronic weight management (8 November 2023)
7. PACE-CME: Phase 2 trial of GIP, GLP-1 and glucagon receptor agonist retatrutide (Jastreboff et al., NEJM 2023)